Primary and secondary tuberculosis preventive treatment in HIV clinics: Simulating alternative strategies

International Journal of Tuberculosis and Lung Disease

Volumn 13, Issue 5, 2009, Pages 652-658

  Basu, S ^a   Maru, D ^a   Poolman, E ^a   Galvani, A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretrovirals; HIV; Isoniazid; Mathematical model; Preventive treatment; Prophylaxis; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; ISONIAZID;

ANTIBIOTIC RESISTANCE; ARTICLE; BOTSWANA; DISEASE SIMULATION; FACE VALIDITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; POSTPRIMARY TUBERCULOSIS; PRIMARY TUBERCULOSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SIMULATION; TUBERCULIN TEST; TUBERCULOSIS CONTROL;

ANTI-RETROVIRAL AGENTS; ANTITUBERCULAR AGENTS; BOTSWANA; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HOSPITALS, SPECIAL; HUMANS; INCIDENCE; MASS SCREENING; MODELS, THEORETICAL; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; PRIMARY PREVENTION; SECONDARY PREVENTION; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 67649562855     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Global TB/HIV Working Group. Isoniazid preventive therapy (IPT) for people living with HIV. Geneva, Switzerland: Stop TB Partnership/WHO, 2001.
2. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2004 (1): CD000171.
3. Bollinger R. HIV and tuberculosis: India's challenges and opportunities. In: Mehra N K, Sharma S K, Sood O P, eds. HIV and tuberculosis: co-infection. Proceedings of the Fifteenth Round Table Conference, 2005. New Delhi, India: Ranbaxy Science Foundation, 2005.
4. Balcells M E, Thomas S L, Godfrey-Faussett P, Grant A D. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis 2006; 12: 744-751.
5. Cohen T, Lipsitch M, Walensky R P, Murray M. Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proc Natl Acad Sci USA 2006; 103: 7042-7047.
6. Dowdy D W, Chaisson R E, Maartens G, Corbett E L, Dorman S E. Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. Proc Natl Acad Sci USA 2008; 105: 11293-11298.
7. Williams B G, Dye C. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science 2003; 301:1535-1537.
8. World Health Organization. Towards universal access. Geneva, Switzerland: WHO, 2008.
9. World Health Organization. Actions for life: towards a world free of tuberculosis. The Global Plan to Stop Tuberculosis 2006-2015. WHO/HTM/STB/2006.35. Geneva, Switzerland: WHO, 2006.
10. Day J H, Charalambous S, Fielding K L, Hayes R J, Churchyard G J, Grant A D. Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South Africa. Int J Tuberc Lung Dis 2006; 10: 523-529.
11. Mohammed A, Ehrlich R, Wood R, Cilliers F, Maartens G. Screening for tuberculosis in adults with advanced HIV infection prior to preventive therapy. Int J Tuberc Lung Dis 2004; 8: 792-795.
12. Churchyard G J, Fielding K, Charalambous S, et al. Efficacy of secondary isoniazid preventive therapy among HIV-infected southern Africans: time to change policy? AIDS 2003; 17: 2063-2070.
13. Cobelens F G, Egwaga S M, van Ginkel T, Muwinge H, Matee M I, Borgdorff M W Tuberculin skin testing in patients with HIV infection: limited benefit of reduced cutoff values. Clin Infect Dis 2006; 43: 634-639.
14. Churchyard G J, Scano F, Grant A D, Chaisson R E. Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. J Infect Dis 2007; 196 (Suppl 1): S52-S62.
15. Rowe K A, Makhubele B, Hargreaves J R, Porter J D, Hausler H P, Pronyk P M. Adherence to TB preventive therapy for HIV-positive patients in rural South Africa: implications for antiretroviral delivery in resource-poor settings? Int J Tuberc Lung Dis 2005; 9: 263-269.
16. Mwinga A, Hosp M, Godfrey-Faussett P, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998; 12: 2447-2457.
17. Quigley M A, Mwinga A, Hosp M, et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 2001; 15: 215-222.
18. Johnson J L, Okwera A, Horn D L, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 2001; 15: 2137-2147.
19. Gordin F M, Matts J P, Miller C, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 1997; 337: 315-320.
20. Hawken M P, Meme H K, Elliott L C, et al. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS 1997; 11: 875-882.
21. Moreno S, Miralles P, Diaz M D, et al. Isoniazid preventive therapy in human immunodeficiency virus-infected persons. Long-term effect on development of tuberculosis and survival. Arch Intern Med 1997; 157: 1729-1734.
22. Rivero A, Lopez-Cortes L, Castillo R, et al. [Randomized trial of three regimens to prevent tuberculosis in HIV-infected patients with anergy]. Enferm Infecc Microbiol Clin 2003; 21: 287-292. [Spanish]
23. van Soolingen D, Borgdorff M W, de Haas P E, et al. Molecular epidemiology of tuberculosis in the Netherlands: a nationwide study from 1993 through 1997. J Infect Dis 1999; 180: 726-736.
24. Blower S M, Dowlatabadi H. Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model, as an example. Int Stat Rev 1994; 2: 229-243.
25. World Health Organization. WHO report 2007. Global tuberculosis control: surveillance, planning, financing. WHO/HTM/TB/2007.376. Geneva, Switzerland: WHO, 2007.
26. Talbot E A, Kenyon T A, Mwasekaga M J, Moeti T L, Mallon V, Binkin N J. Control of anti-tuberculosis drug resistance in Botswana. Int J Tuberc Lung Dis 2003; 7: 72-77.
27. Kenyon T A, Mwasekaga M J, Huebner R, Rumisha D, Binkin N, Maganu E. Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana. Int J Tuberc Lung Dis 1999; 3: 4-11.
28. Currie C S, Williams B G, Cheng R C, Dye C. Tuberculosis epidemics driven by HIV: is prevention better than cure? AIDS 2003; 17: 2501-2508.
29. Heymann S J. Modelling the efficacy of prophylactic and curative therapies for preventing the spread of tuberculosis in Africa. Trans R Soc Trop Med Hyg 1993; 87: 406-411.
30. Guwatudde D, Debanne S M, Diaz M, King C, Whalen CC. A re-examination of the potential impact of preventive therapy on the public health problem of tuberculosis in contemporary sub-Saharan Africa. Prev Med 2004; 39: 1036-1046.
31. Brewer T F, Heymann S J, Colditz G A, et al. Evaluation of tuberculosis control policies using computer simulation. JAMA 1996; 276: 1898-1903.
32. Williams B G, Granich R, Chauhan L S, Dharmshaktu N S, Dye C. The impact of HIV/AIDS on the control of tuberculosis in India. Proc Natl Acad Sci USA 2005; 102: 9619-9624.
33. Over M, Heywood P, Gold J, Gupta I, Hira S, Marseille E. HIV/AIDS treatment and prevention in India: modeling the costs and consequences. Washington DC, USA: The World Bank, 2004.
34. World Health Organization. WHO report 2008. Global tuberculosis control-surveillance, planning, financing. WHO/HTM/TB/2008.393. Geneva, Switzerland: WHO, 2008.
35. Paramasivan C N, Venkataraman P. Drug resistance in tuberculosis in India. Indian J Med Res 2004; 120: 377-386.
36. Golub J E, Saraceni V, Cavalcante S, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007; 21: 1441-1448.